Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study

BackgroundBrentuximab vedotin (BV) has demonstrated high remission rates in clinical trials for systemic anaplastic large cell lymphoma (sALCL), yet its real-world effectiveness in China remains unconfirmed. This retrospective observational study evaluates BV-based regimens in patients with sALCL, t...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhiqiang Zhao, Qinchuan Yu, Liping Su, Jianxia He, Jie Tao, Yanfeng Xi, Yujiao Guo, Yanhong Luo, Lieyang Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1494384/full
Tags: Add Tag
No Tags, Be the first to tag this record!